Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Yttrium-90 ibritumomab tiuxetan with rituximab for primary CNS non-Hodgkin lymphoma has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Primary Central Nervous System Non-Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-07-20